Guillain-Barre Syndrome

Key Points

• Guillain-Barre syndrome is a rare autoimmune disorder causing progressive weakness and possible paralysis.
• Weakness often begins in both legs and ascends to arms and upper body.
• Progression can occur over hours to weeks, and respiratory-muscle involvement can be fatal.
• Recovery commonly starts within weeks, but full recovery duration is variable and residual deficits may persist.
• Core treatments include plasma exchange and high-dose immunoglobulin therapy.
• High-risk complications include autonomic instability, aspiration, thromboembolism, skin injury, and bladder/bowel dysfunction.

Pathophysiology

GBS is an autoimmune-mediated peripheral nerve disorder characterized by rapidly progressive weakness, often with ascending distribution from lower to upper extremities. In severe cases, respiratory muscles are affected and life-threatening ventilatory failure can occur.

Common antecedents include Campylobacter jejuni gastroenteritis and viral illnesses such as influenza. In some patients, recent surgery or (rarely) vaccine exposure can precede onset. Immune attack may target myelin or axons, causing conduction failure and motor decline.

Classification

• Progressive weakness phase: Rapidly evolving ascending motor weakness with possible progression to paralysis.
• Recovery phase: Improvement usually begins within weeks but may extend over months to years.
• AIDP: Most common demyelinating form with ascending weakness pattern.
• Miller Fisher syndrome: Variant commonly beginning with ophthalmoplegia pattern.
• AMAN: Predominantly motor axonal form with reflex loss and relative sensory preservation.
• AMSAN: Axonal form with both motor and sensory involvement.

Nursing Assessment

NCLEX Focus

Trend progression speed and respiratory involvement continuously.

• Assess distribution and progression of weakness and paresthesia.
• Assess for signs of respiratory-muscle compromise and fatigue.
• Assess for swallowing and speech impairment with aspiration risk.
• Assess for autonomic instability cues (heart-rate and blood-pressure lability).
• Assess functional decline pace to support timely escalation.
• Assess for secondary complications from immobility, including pressure injury, venous thromboembolism cues, and bladder/bowel dysfunction.
• Anticipate lumbar-puncture/CSF findings that can include elevated protein patterns.
• Anticipate electrophysiologic support testing: NCV often shows slowed peripheral conduction in neuropathic patterns such as GBS.
• Anticipate EMG abnormalities (for example prolonged or absent F-wave responses) in advanced diagnostic pathways.

Nursing Interventions

• Escalate immediately when weakness progresses rapidly or breathing becomes compromised.
• Coordinate definitive therapy pathways (plasma exchange and high-dose immunoglobulin) with close monitoring.
• Apply aspiration precautions and position upright during meals when bulbar weakness is present.
• Support respiratory care (airway clearance, breathing support, and escalation for ventilatory decline).
• Implement pressure-injury and thrombosis prevention measures during reduced mobility phases.
• Monitor bowel/bladder patterns and support elimination management.
• Support mobility safety and ADL assistance during progressive and recovery phases.

Evaluation of Outcomes

• Trend oxygenation and respiratory effort for early recovery of neuromuscular ventilation.
• Evaluate swallowing safety and oral-intake tolerance without aspiration.
• Evaluate mobility and range-of-motion improvement with or without assistive support.
• Reassess pain, skin integrity, and autonomy in activities of daily living over recovery phases.

Respiratory Failure Risk

GBS can deteriorate quickly; delayed escalation can be fatal when respiratory muscles are affected.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
immune-globulins	High-dose IVIG	Used as disease-targeted therapy to reduce autoimmune attack burden in acute GBS management.

Clinical Judgment Application

Clinical Scenario

A patient reports bilateral leg tingling that progressed to arm weakness over 48 hours with increasing shortness of breath.

• Recognize Cues: Ascending weakness with early respiratory involvement.
• Analyze Cues: Acute autoimmune neuropathy progression is likely.
• Prioritize Hypotheses: Prevent respiratory failure and irreversible complications.
• Generate Solutions: Activate urgent neurologic/respiratory monitoring and treatment pathway.
• Take Action: Prepare for rapid supportive escalation and disease-specific therapy.
• Evaluate Outcomes: Progression slows and respiratory status remains supported.

Related Concepts

• immune-globulins - High-dose IVIG therapy in autoimmune neuromuscular disease.
• nursing-care-priorities-for-neuromuscular-impairment - Shared airway and mobility-risk priorities.
• collaborative-and-environmental-neuromuscular-care - Interdisciplinary planning for progressive weakness.

Self-Check

1. Which symptom pattern is most characteristic of early GBS progression?
2. Why is respiratory assessment a top priority in acute GBS?
3. Which infections are commonly associated with preceding GBS onset?